Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
Jessina C McGregor, George P Allen, David T BeardenOregon State University College of Pharmacy, Portland, OR, USAAbstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2008-11-01
|
Series: | Therapeutics and Clinical Risk Management |
Online Access: | http://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--a2541 |
id |
doaj-cb6273e41a0942eab0655f62590169c7 |
---|---|
record_format |
Article |
spelling |
doaj-cb6273e41a0942eab0655f62590169c72020-11-24T23:54:30ZengDove Medical PressTherapeutics and Clinical Risk Management1176-63361178-203X2008-11-012008Issue 5843853Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritisJessina C McGregorGeorge P AllenDavid T BeardenJessina C McGregor, George P Allen, David T BeardenOregon State University College of Pharmacy, Portland, OR, USAAbstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofloxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofl oxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials. Insufficient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specific complicating factors. Levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofloxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofl oxacin within specific patient sub-populations.Keywords: urinary tract infection, pyelonephritis, levofloxacin http://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--a2541 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jessina C McGregor George P Allen David T Bearden |
spellingShingle |
Jessina C McGregor George P Allen David T Bearden Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis Therapeutics and Clinical Risk Management |
author_facet |
Jessina C McGregor George P Allen David T Bearden |
author_sort |
Jessina C McGregor |
title |
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |
title_short |
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |
title_full |
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |
title_fullStr |
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |
title_full_unstemmed |
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |
title_sort |
levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis |
publisher |
Dove Medical Press |
series |
Therapeutics and Clinical Risk Management |
issn |
1176-6336 1178-203X |
publishDate |
2008-11-01 |
description |
Jessina C McGregor, George P Allen, David T BeardenOregon State University College of Pharmacy, Portland, OR, USAAbstract: Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofloxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofl oxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials. Insufficient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specific complicating factors. Levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofloxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofl oxacin within specific patient sub-populations.Keywords: urinary tract infection, pyelonephritis, levofloxacin |
url |
http://www.dovepress.com/levofloxacin-in-the-treatment-of-complicated-urinary-tract-infections--a2541 |
work_keys_str_mv |
AT jessinacmcgregor levofloxacininthetreatmentofcomplicatedurinarytractinfectionsandacutepyelonephritis AT georgepallen levofloxacininthetreatmentofcomplicatedurinarytractinfectionsandacutepyelonephritis AT davidtbearden levofloxacininthetreatmentofcomplicatedurinarytractinfectionsandacutepyelonephritis |
_version_ |
1716255033896468480 |